About Us

HemoShear works in close partnerships with pharmaceutical and other companies to test and explore in the laboratory the effects of new drug compounds and other chemicals on humans. Our proprietary technology provides the world’s only validated, cell-based human surrogate models of organ systems that can predict effects on the human body at early stages in the drug development cycle.

Our breakthrough, human surrogate technology is based upon the principal that shear stress forces from blood flow are necessary survival factors for human cells. HemoShear’s technology imposes human-derived hemodynamic (blood flow) forces on human primary cells to recreate their human biology. Our proof of concept studies demonstrate that HemoShear’s technology is far more predictive of human responses than traditional cell culture and animal testing.

HemoShear’s technology accelerates drug R&D and reduces costly failures by providing the world’s most physiologically relevant environments for discovering and assessing new drug candidates.

The intellectual property (IP) is fully owned by HemoShear. A non-provisional patent application was filed in January 2008, and the company continues to file additional applications to protect its IP nationally and internationally.